MMV390048 40mg
MMV_MMV390048_16_01, Part B
Phase 2 small_molecule completed
Quick answer
MMV390048 40mg for Malaria is a Phase 2 program (small_molecule) at CNS Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CNS Pharmaceuticals
- Indication
- Malaria
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed